Linear Diagnostics specializes in next-generation near-patient diagnostics, particularly for sexually transmitted infections (STIs) and other infectious diseases. Their innovative technology combines linear dichroism and an amplification method known as EXPAR, enabling rapid and accurate results in under 15 minutes. The linear dichroism technique detects shifts in the plane of polarized light when a target binds to a detector, allowing for the simultaneous measurement of multiple targets. This capability is enhanced by the use of various molecular recognition methods, such as antibodies for antigens and oligonucleotides for capturing complementary DNA sequences. 

The diagnostic system is designed for Point-of-Care testing, utilizing a portable, low-cost reader paired with a single-use, disposable self-sampling cartridge. This setup not only simplifies the testing process but also significantly reduces the time-to-result compared to traditional PCR methods. The isothermal nature of EXPAR eliminates the need for complex heating and cooling cycles, making the technology more accessible and user-friendly. Additionally, the system's compact design allows it to operate on an internal rechargeable battery, making it suitable for use in various settings without the need for mains power or computer access.

United Kingdom

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent. Such a solution has applications in a number of high-value sectors including health, food, defence and security. LDL has also established development partnerships with a number of end users including clinical microbiology, food producers and defence medicine.

Linear Diagnostics

Company Details